Antimicrobials
Amoxicillin-Clavulanate IV

Amoxicillin-Clavulanate IV

High
N/A

Dosing

General Information

Clinically indicated for treatment of polymicrobial community acquired infections infections in patients not able to take oral amoxicillin-clavulanate, such as:

  • Skin and soft tissue infections suspected to be polymicrobial or have Gram-negative involvement (e.g. polymicrobial diabetic foot infections greater than 4 weeks duration, groin/rectal involvement or bite wound infections)
  • Severe odontogenic infections
  • Intra-abdominal infections (e.g. peritonitis, abscess, diverticulitis, appendicitis, cholangitis)
  • Polymicrobial respiratory tract infections (e.g. aspiration pneumonia in individuals with risk factors for anaerobic involvement)
  • Use narrower spectrum antibiotics, (in combination if necessary), in preference to amoxicillin-clavulanic acid when possible, such as: ampicillin + metronidazole, cefazolin + metronidazole or cefuroxime + metronidazole.
  • No activity against Pseudomonas aeruginosa - DO NOT use if clinical history or cultures indicate that P. aeruginosa may be involved in infection.
  • Monitor for signs and symptoms of a hypersensitivity reaction
  • With prolonged therapy, monitor renal, hepatic, and hematologic function periodically
  • Patients with hepatic impairment, monitor liver function tests at regular intervals
  • Allergy/rash (immediate or delayed)
  • Note Epstein-Barr viral related rash
  • Cytopenias
  • GI: diarrhea (especially with higher clavulanic acid doses), nausea, vomiting.
  • C. difficile infection
  • Hepatotoxicity due to clavulanate - usually mild, liver failure is rare.

Amoxicillin-Clavulanate - Horizon Parenteral Drug Manual Monograph

(available only from the desktop version of Firstline through Horizon computers)

Antimicrobial class: Aminopenicillin + Beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Therapeutic